Literature DB >> 6054907

Pyrrolidinomethyltetracycline in cavernous sinus thrombosis.

B B Khare.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1967        PMID： 6054907      PMCID： PMC506478          DOI： 10.1136/bjo.51.10.712

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  6 in total

1.  Clinical and laboratory experiences with a new intravenous tetracycline derivative.

Authors:  H A WEIZEL; D DANA
Journal:  Can Med Assoc J       Date:  1961-11-11       Impact factor: 8.262

2.  [Experimental and clinical studies on the tetracycline derivative reverin in ophthalmology].

Authors:  H J KUCHLE; Th DIMMLING
Journal:  Ophthalmologica       Date:  1961-04       Impact factor: 3.250

3.  Treatment of 1300 patients with repeated intravenous doses of pyrrolidinomethyl tetracycline.

Authors:  E KOCH; H BOHN
Journal:  Antibiotic Med Clin Ther (New York)       Date:  1960-04

4.  [Experimental & clinical studies on N-pyrrilidinomethyl-tetracycline (Reverin)].

Authors:  T DIMMLING; H HUNER; W LUTZEYER; G SIMON
Journal:  Munch Med Wochenschr       Date:  1958-04-25

5.  Clinical and laboratory observations of a new antibiotic, tetracycline.

Authors:  M FINLAND; E M PURCELL; S S WRIGHT; B D LOVE; T W MOU; E H KASS
Journal:  J Am Med Assoc       Date:  1954-02-13

6.  [Comparative microbiological studies on N-pyrrolidinomethyl-tetracycline (reverin) & tetracycline HCl].

Authors:  R FUSSGANGER
Journal:  Munch Med Wochenschr       Date:  1958-04-25
  6 in total
  2 in total

1.  Cavernous sinus thrombosis revisited.

Authors:  C T Yarington
Journal:  Proc R Soc Med       Date:  1977-07

2.  Pyrrolidinomethyl tetracycline in cavernous sinus thrombosis.

Authors:  S R Malik; A K Gupta; G Singh; S Choudhry
Journal:  Br J Ophthalmol       Date:  1970-02       Impact factor: 4.638
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.